Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study

• Conditions: Cholangiocarcinoma

• Registration Number: NCT04243057
• Lead Sponsor: Beijing Tsinghua Chang Gung Hospital

Brief Summary

This is a multicenter, two-way, non-intervention study. the main purpose: Understand the current status of diagnosis and treatment of cholangiocarcinoma patients in China and observe the effect of different treatment options on patient recurrence and long-term survival

Secondary purpose:

1. Exploring the actual clinical treatment situation and its compliance with the existing diagnosis and treatment of bile duct cancer

2. Exploring the establishment of clinical research standard fields and standards for diagnosis and treatment of bile duct cancer

Detailed Description

Not available

Study Timeline

• Study Start: 2019-08-30
• Status Verified: 2020-01
• Study First Submitted: 2020-01-24
• Study First Submitted QC: 2020-01-24
• Last Update Submitted: 2020-01-24
• Study First Posted: 2020-01-27
• Last Update Posted: 2020-01-27
• Primary Completion: 2022-09-30
• Study Completion: 2022-09-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 5000

Inclusion Criteria

1. above the age of 18 years old, male or female
2. clinical diagnosis of patients with cholangiocarcinoma
3. Child-Pugh classification of A, B
4. Eastern Cooperative Oncology Group scoring system (ECOG) score of 0-2 points

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
RFSR	3 years	RFSR-Recurrence Free Survival Rate

Secondary Outcome Measures

Name	Time	Method
OS	3 years	OS-Overall Survival
RFS	3 years	RFS-Recurrence Free Survival

Trial Locations

Locations (1)

Beijing Tsinghua Changgung Hospital; 🇨🇳 Beijing, Beijing, China